Depression is a severe and life-threatening psychiatric illness whose pathogenesis is still essentially unknown. Proteomic analysis of synaptic terminals (synaptoproteomics) in animal models of depression is a powerful approach to gain insight into the molecular mechanisms underlying vulnerability to mood disorders and the long-term action of drug treatments. Here, we employed two different animal models of depression, the Learned Helplessness rats (a classical behavioral model of depression) and a new model of depression with gene - environment interaction (Flinders Sensitive Line rats subjected to early life stress). Both animal models were treated with the antidepressant escitalopram. Analysis of their synaptoproteomic profile revealed a number of protein spots differently regulated by basic vulnerability and/or early life stress. Using this approach, we obtained information regarding biomarkers that may represent predictors of pathology or response/resistance to drug treatment, as well as potential targets for novel pharmacological and therapeutic strategies.
Mallei, A., Giambelli, R., EL KHOURY, A., Gruber, S., Musazzi, L., Barbiero, V., et al. (2009). Synaptoproteomics of existing and new animal models of depression. In C.W. Turck (a cura di), Biomarkers for Psychiatric Disorders (pp. 185-202). Springer [10.1007/978-0-387-79251-4_8].
Synaptoproteomics of existing and new animal models of depression
L. MUSAZZI;
2009
Abstract
Depression is a severe and life-threatening psychiatric illness whose pathogenesis is still essentially unknown. Proteomic analysis of synaptic terminals (synaptoproteomics) in animal models of depression is a powerful approach to gain insight into the molecular mechanisms underlying vulnerability to mood disorders and the long-term action of drug treatments. Here, we employed two different animal models of depression, the Learned Helplessness rats (a classical behavioral model of depression) and a new model of depression with gene - environment interaction (Flinders Sensitive Line rats subjected to early life stress). Both animal models were treated with the antidepressant escitalopram. Analysis of their synaptoproteomic profile revealed a number of protein spots differently regulated by basic vulnerability and/or early life stress. Using this approach, we obtained information regarding biomarkers that may represent predictors of pathology or response/resistance to drug treatment, as well as potential targets for novel pharmacological and therapeutic strategies.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
